EUVIMEDEUVIMED entdecken
Multizentrische Studie

Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Gary C Brown, Melissa M Brown, Meg C Monigle

Ophthalmology Retina · 2024

DOI: 10.1016/j.oret.2023.11.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmology Retina, 2024. Verfasst von Gary C Brown und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoeconomics, Center for Value-Based Medicine, Hilton Head, South Carolina; Wills Eye Hospital, Philadelphia, Pennsylvania; Sidney…. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Cost-Benefit Analysis, Intravitreal Injections, Ranibizumab. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To quantify the cost-utility ratio of the ranibizumab Port Delivery System (PDS; SUSVIMO) versus intravitreal ranibizumab injections for treating neovascular age-related macular degeneration (nAMD) based upon Archway Phase 3 Trial data. DESIGN: Cost-utility analysis. SUBJECTS: Archway Phase 3 Clinical Trial nAMD participants previously responsive to anti-VEGF therapy were randomized 3:2. Two hundred forty received PDS refills q 24 weeks and 162 received ranibizumab injections. METHODS: Ophthalmic patient, time tradeoff utilities, direct medical and societal cost perspectives, 12-year, 1-year, and 5-year timelines, United States 2022 real dollars, and a 3% annual discount rate were employed. Utilities were adjusted for nAMD conversion in fellow eyes during the 12-year, mean participant life expectancy. Premature death associated with severe vision loss was integrated as per the population-based Salisbury Eye Evaluation Study. MAIN OUTCOME MEASURES: Quality-adjusted life-year (QALY) accruals, costs, and incremental and average cost-utility ratios in $/QALY (dollars expended per QALY gained). RESULTS: Versus no therapy, the 1-year PDS QALY gain was 0.0156 (6.8%) versus 0.0063 (0.82%) for intravitreal injections (P < 0.001), whereas the respective 12-year QALY gains were 1.714 (28%) and 1.639 (26.8%) (P = 0.99). One-year direct PDS ophthalmic costs totaled $21 825 with 2 ranibizumab fills, whereas ranibizumab injection therapy totaled $18 405 with 11.8 injections. The 1-year incremental PDS $/QALY versus injections was cost effective at $75 497/QALY. Five-year PDS therapy was not incrementally cost effective at $304 108/QALY, nor was the 12-year therapy at $761 646/QALY. Average 12-year cost-utility ratios were $78 773/QALY for the PDS and $47 917/QALY for injection therapy. Adding -$476 442 12-year offsetting societal costs netted $314 521 to society per PDS participant versus $370 958 per participant for injection therapy. CONCLUSIONS: Ranibizumab PDS therapy was not incrementally cost effective versus ranibizumab injection therapy at 12 or 5 years but was at 1 year. Injection therapy had a more favorable 12-year average cost-utility ratio. Vision gain was the major determinant of participant value gain and was the same for both interventions. Both interventions were highly cost effective utilizing average cost-utility analysis with the societal cost perspective. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsCost-Benefit AnalysisIntravitreal InjectionsRanibizumabVisual AcuityWet Macular DegenerationAgedFemaleHumansMaleDrug Delivery SystemsFollow-Up StudiesQuality of LifeQuality-Adjusted Life YearsTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

Cost-utility analysisMacular degenerationPatient preferences cost-benefitRanibizumab Port Delivery SystemRanibizumab injections

Substanzen

Angiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Pharmacoeconomics, Center for Value-Based Medicine, Hilton Head, South Carolina; Wills Eye Hospital, Philadelphia, Pennsylvania; Sidney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia,…
  • Beverly Hospital, Beth Israel Lahey Health, Beverly, Massachusetts.

Zitieren

APA

Brown, G. C., Brown, M. M., & Monigle, M. C. (2024). Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2023.11.002

Vancouver

Brown GC, Brown MM, Monigle MC. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 2024. doi:10.1016/j.oret.2023.11.002

BibTeX
@article{Brown2024,
  author = {Brown, Gary C and Brown, Melissa M and Monigle, Meg C},
  title = {Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration},
  journal = {Ophthalmology Retina},
  year = {2024},
  doi = {10.1016/j.oret.2023.11.002}
}
Kostenlos starten →